Gynecologic Cancers: Expert Guidance for Community Practice

Join us for a live CME/CE/CPE-certified Interdisciplinary Team Workshop Series to hear from experts on the latest data and therapeutic options for patients with endometrial, ovarian, and cervical cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Welcome, Introduction, Polling, and Presurvey Questions

Advances in Current Management of Endometrial Cancers

  • Advances in the treatment landscape
    • New clinical data
    • New approvals
  • Management of immune-related AEs
  • Novel therapies in development
    • Case-based discussion of current data

Advances in Frontline and Recurrent Ovarian Cancers

  • Testing for BRCA1/2 and HRD status
  • PARPi in frontline and recurrent ovarian cancer
  • Novel therapies in development
    • Case-based discussion of current data

Advances in Current Management of Cervical Cancers

  • Cervix cancer overview
    • HPV Infection and tumorigenesis
    • HPV vaccination and preventative measures
  • Current treatments algorithms for advanced/metastatic cervix cancer
  • Novel therapies in development
    • Immunotherapy
    • Antibody–drug conjugates
    • PARP inhibitors
    • Case-based discussion of current data

Audience Q&A Session


Date / Time
Event Details


Program Director
David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Program Director
Ritu Salnai, MD

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Floor Backes, MD

Professor, Obstetrics & Gynecology
Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center and James Cancer Hospital
Columbus, Ohio

Maria Bell, MD, MPH, MBA

Medical Director of Research
Gynecologic Oncologist
Sanford Health
Sioux Falls, South Dakota

Hye Sook Chon, MD

Associate Professor
Associate Member
Clinical Trials Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Elizabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Bhavana Pothuri, MD, MS

Gynecologic Oncology Clinical Trials
Department of Ob/Gyn
Department of Medicine
Perlmutter Cancer Center
NYU Langone Health
NYU Grossman School of Medicine
New York, New York

Lauren Prescott, MD

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor & Division Director
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of California, Irvine
Irvine, California
University of California, Irvine Medical Center
Orange, California

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with gynecologic malignancies.

Target Audience
This program is intended for medical oncologists, gynecologic oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess for appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate current and emerging practice-changing clinical data on ICIs and PARP inhibitors as single-agent or combination therapies in cervical, endometrial, and ovarian cancer
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of ICI-based therapy in endometrial cancer classified as microsatellite stable


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN for Live Meetings: JA4008176-0000-21-182-L01-P

UAN for Simulcasts: JA4008176-0000-21-183-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.